Amit Sharma, MD, and his collaborators at the Boise Kidney and Hypertension Institute in Meridan, Idaho, tested the product, trademarked MV-ONE, in 25 HD patients in an open-label, non-blinded, non-randomized single-site study. Patients took the multivitamin once daily with food for 12 weeks. The product, which is made by Nephrian Inc., of Thousand Oaks, Calif., contains cholecalciferol 1500 IU, gamma-tocopherol 300 mg, and alpha lipoic acid 600 mg. Nephrian sponsored the study.
MV-ONE treatment significantly increased 25-hydroxyvitamin levels by a mean of 33% and significant decreased epoetin alfa dosing by a mean of 34%, according to findings presented at the National Kidney Foundation’s Spring Clinical Meetings.
The researchers stated that the nutraceutical increases active vitamin D blood levels in HD patients, thus identifying its efficacious ability to potentiate treatment for SHPT. By decreasing requirements for erythropoiesis-stimulating agents, it could aid in treating anemia stemming from renal disease.
The antioxidative properties of the nutraceutical “may be a useful cost-effective adjuvant in an increasingly challenging clinical environment,” the authors concluded.